NeelanjanRayMD

PubMed

• 13 citations
  HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind s...
  William F. C. Rigby, Jane H. Buckner, S. Louis Bridges, Marleen Nys, S. Gao, Martin Polinsky, Neelanjana Ray, Vivian P. Bykerk> ;Arthritis Research & Therapy. 2021 Sep 18
• 50 citations
  Efficacy and safety of abatacept in active primary Sjögren's syndrome: Results of a phase III, randomised, placebo-controlled trial
  Alan N. Baer, Jacques-Eric Gottenberg, E. William St. Clair, Takayuki Sumida, Tsutomu Takeuchi, Raphaèle Seror, Gary N. Foulks, Marleen Nys, Sumanta Mukherjee, R. Wong...> ;Annals of the Rheumatic Diseases. 2021 Mar 1
• 13 citations
  Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.
  Ira B. Dicker, Sharon Zhang, Neelanjana Ray, Brett R. Beno, Alicia Regueiro-Ren, Samit R Joshi, Mark I. Cockett, Mark Krystal, Max Lataillade> ;Plos One. 2019 Oct 17
• 17 citations
  Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administer...
  Carey Hwang, Dirk Schürmann, Christian Sobotha, Marta Boffito, Heather Sevinsky, Neelanjana Ray, Palanikumar Ravindran, Hong Xiao, Christian Keicher, Andreas Hüser, Ma...> ;Clinical Infectious Diseases. 2017 Aug 1
• 170 citations
  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
  Ronald J. Bosch, Justin Ritz, Jason M. Hataye, Evgenia Aga, Randall Tressler, Stephen W. Mason, Carey Hwang, Dennis M. Grasela, Neelanjana Ray, Josh C Cyktor, John M. ...> ;The Journal of Infectious Diseases. 2017 Jun 1
• 7 citations
  The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.
  Neelanjana Ray, Tianbo Li, Zeyu Lin, Tricia Protack, Petronella Maria van Ham, Carey Hwang, Mark Krystal, Monique Nijhuis, Max Lataillade, Ira B. Dicker> ;Journal of Acquired Immune Deficiency Syndromes. 2017 May 1
• 7 citations
  Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded...
  Samir K. Gupta, Grace A. McComsey, John Lombaard, Juan Echevarria, Catherine Orrell, Anchalee Avihingsanon, Olayemi Osiyemi, Mario Santoscoy, Neelanjana Ray, David A. ...> ;The Lancet. HIV. 2016 Jan 1
• 49 citations
  Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068
  Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, Neelanjana Ray, Betsy J. Eggers, Hua Fang, Li Fan, Matthew D. Healy, David R. Langley, Carey Hwang, Max Lataillade, G...> ;The Journal of Antimicrobial Chemotherapy. 2014 Mar 1
• 59 citations
  Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to...
  Zhufang Li, Nannan Zhou, Yongnian Sun, Neelanjana Ray, Max Lataillade, George J. Hanna, Mark Krystal> ;Antimicrobial Agents and Chemotherapy. 2013 Sep 1
• 37 citations
  Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-66...
  Neelanjana Ray, Carey Hwang, Matthew D. Healy, Jeannette M. Whitcomb, Max Lataillade, Megan Wind-Rotolo, Mark Krystal, George J. Hanna> ;Journal of Acquired Immune Deficiency Syndromes. 2013 Sep 1
• 77 citations
  Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1–Infected Subjects
  Richard E. Nettles, Dirk Schürmann, Li Zhu, Michele Stonier, Shu-Pang Huang, Ih Chang, Caly Chien, Mark Krystal, Megan Wind-Rotolo, Neelanjana Ray, George J. Hanna, Ri...> ;The Journal of Infectious Diseases. 2012 Oct 1
• 102 citations
  In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068
  Beata Nowicka-Sans, Yi-Fei Gong, Brian McAuliffe, Ira B. Dicker, Hsu-Tso Ho, Nannan Zhou, Betsy J. Eggers, Pin-Fang Lin, Neelanjana Ray, Megan Wind-Rotolo, Li Zhu, Ant...> ;Antimicrobial Agents and Chemotherapy. 2012 Jul 1
• 135 citations
  Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model.
  Kang Woo Lee, Walter Chen, Eunsung Junn, Joo Young Im, Hilary Grosso, Patricia K. Sonsalla, Xuyan Feng, Neelanjana Ray, José R. Fernández, Yang Chao, Eliezer Masliah, ...> ;The Journal of Neuroscience. 2011 May 11
• 46 citations
  HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
  John C. Tilton, Heather Amrine-Madsen, John L. Miamidian, Kathryn M. Kitrinos, Jennifer M. Pfaff, James F. Demarest, Neelanjana Ray, Jerry Jeffrey, Celia C. LaBranche,...> ;AIDS Research and Human Retroviruses. 2010 Feb 2
• 37 citations
  Study of Andes virus entry and neutralization using a pseudovirion system.
  Neelanjana Ray, Jillian Whidby, Shaun M. Stewart, Jay W. Hooper, Andrea Bertolotti-Ciarlet> ;Journal of Virological Methods. 2010 Feb 1
• 29 citations
  Fos Proteins Suppress Dextran Sulfate Sodium-Induced Colitis through Inhibition of NF-κB
  Yasunari Takada, Neelanjan Ray, Eiji Ikeda, Tomohiro Kawaguchi, Masayoshi Kuwahara, Erwin F. Wagner, Koichi Matsuo> ;Journal of Immunology. 2010 Jan 15
• 34 citations
  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
  Pavel Pugach, Neelanjana Ray, Per Johan Klasse, Thomas J. Ketas, Elizabeth Michael, Robert W. Doms, Benhur Lee, John P. Moore> ;Virology. 2009 May 10
• 43 citations
  HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide
  Neelanjana Ray, Leslie A. Blackburn, Robert W. Doms> ;Journal of Virology. 2009 Apr 1
• 13 citations
  Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.
  Jessamina E. Harrison, Jonathan B. Lynch, Luz-Jeannette Sierra, Leslie A. Blackburn, Neelanjana Ray, Ronald G. Collman, Robert W. Doms> ;Journal of Virology. 2008 Dec 1
• 19 citations
  Maraviroc in the treatment of HIV infection.
  Neelanjana Ray> ;Drug Design, Development and Therapy. 2008 Aug 20
• 23 citations
  N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.
  Antu K. Dey, Kathryn B. David, Neelanjana Ray, Thomas J. Ketas, Per Johan Klasse, Robert W. Doms, John P. Moore> ;Virology. 2008 Mar 1
• 55 citations
  Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors
  Neelanjana Ray, Jessamina E. Harrison, Leslie A. Blackburn, Jeffrey N. Martin, Steven G. Deeks, Robert W. Doms> ;Journal of Virology. 2007 Apr 1
• 22 citations
  c-Fos-Deficient Mice Are Susceptible to Salmonella enterica Serovar Typhimurium Infection
  Kenta Maruyama, Gen Ichiro Sano, Neelanjan Ray, Yasunari Takada, Koichi Matsuo> ;Infection and Immunity. 2007 Mar 1
• 87 citations
  Receptor Activator of NF-κB Ligand and Osteoprotegerin Regulate Proinflammatory Cytokine Production in Mice
  Kenta Maruyama, Yasunari Takada, Neelanjan Ray, Yukiko Kishimoto, Josef M. Penninger, Hisataka Yasuda, Koichi Matsuo> ;Journal of Immunology. 2006 Sep 15
• 78 citations
  c-Fos suppresses systemic inflammatory response to endotoxin
  Neelanjan Ray, Masayoshi Kuwahara, Yasunari Takada, Kenta Maruyama, Tomohiro Kawaguchi, Hirokazu Tsubone, Hiromichi Ishikawa, Koichi Matsuo> ;International Immunology. 2006 May 1
• Join now to see all